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Abstract
Background: Few studies have investigated the management of human immunodeficiency virus (HIV)-associated
end-stage renal failure particularly in low-resource settings with limited access to renal replacement therapy. We
aimed to evaluate the effects of HIV infection on continuous ambulatory peritoneal dialysis (CAPD)-associated
peritonitis outcomes and technique failure in highly active antiretroviral therapy (HAART)-treated HIV-positive
CAPD populations.
Methods: We conducted a single-center prospective cohort study of consecutive incident CAPD patients
recruited from two hospitals in Durban, South Africa from September 2012-February 2015. Seventy HIV-negative
and 70 HIV-positive end-stage renal failure patients were followed monthly for 18 months at a central renal clinic.
Primary outcomes of peritonitis and catheter failure were assessed for the first 18 months of CAPD therapy.
We assessed risk factors for peritonitis and catheter failure using Cox regression survival analysis.
Results: The HIV-positive cohort had a significantly increased rate of peritonitis compared to the HIV-negative
cohort (1.86 vs. 0.76 episodes/person-years, respectively; hazard ratio [HR], 2.41; 95% confidence interval [CI], 1.69–3.45,
P < 0.001). When the baseline CD4 count was below 200 cells/μL, the peritonitis rate rose to 3.69 episodes/person-years
(HR 4.54, 95% CI 2.35–8.76, P < 0.001), while a baseline CD4 count above 350 cells/μL was associated with a peritonitis
rate of 1.60 episodes/person-years (HR 2.10, CI 1.39–3.15, P = 0.001). HIV was associated with increased hazards of
peritonitis relapse (HR, 3.88; CI, 1.37–10.94; P = 0.010). Independent predictors associated with increased peritonitis risk
were HIV (HR, 1.84; CI, 1.07–3.16; P = 0.027), diabetes (HR, 2.09; CI, 1.09–4.03; P = 0.027) and a baseline CD4 count
< 200 cells/μL (HR, 3.28; CI, 1.42–7.61; P = 0.006). Catheter failure rates were 0.34 (HIV-positive cohort) and 0.24
(HIV-negative cohort) episodes/person-years (HR, 1.42; 95% CI, 0.73–2.73; P = 0.299). Peritonitis (HR, 14.47; CI, 2.79–75.
00; P = 0.001), average hemoglobin concentrations (HR, 0.75; CI, 0.59–0.95; P = 0.016), and average serum C-reactive
protein levels were independent predictors of catheter failure.
Conclusions: HIV infection in end-stage renal disease patients managed by CAPD was associated with increased
peritonitis risk; however, HIV infection did not increase the risk for CAPD catheter failure rate at 18 months.
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Background
Continuous ambulatory peritoneal dialysis (CAPD) is
the dialysis modality of choice for many patients with
end-stage renal disease (ESRD) and a cost-effective op-
tion easily implemented in low-resource settings [1–3].
However, peritonitis presents an ongoing challenge and
is a major cause of technical failure [4–6], particularly
under poor socioeconomic conditions and in immuno-
compromised patients [7, 8]. Considerable advancement
has been made in CAPD management over the last de-
cades leading to a substantial decrease in peritonitis
rates, with as few as 1 case/51 patient–months reported
by some authors [9]. However, peritonitis remains an
important factor influencing CAPD-associated mor-
bidity and mortality, and certain organisms, such as
fungi and Gram-negative bacteria, are associated
with worse outcomes [10–12]. Although reports are
inconsistent, some of the factors associated with
increased peritonitis risks are age, race, sex, comor-
bidities (diabetes, human immunodeficiency virus
[HIV]), socioeconomic status, smoking, higher body
mass index (BMI), malnutrition and chronic inflam-
mation [4, 8, 13–16].
HIV infection presents a unique challenge in pa-
tients with ESRD managed with CAPD. As HIV im-
pairs local host defense mechanisms [16], the risk of
peritonitis in this population may be influenced by
the adequacy of viral control and the patient’s im-
munologic state [8, 17]. Furthermore, the protein
and amino acid losses frequently observed in CAPD
may aggravate the malnutrition and hypoalbumin-
emia common in HIV infection, which can further
compound the risk of peritonitis [18–20]. The rates
of non-communicable diseases such as chronic kid-
ney diseases (CKD) among HIV-positive populations
are expected to rise significantly, as highly active
antiretroviral therapy (HAART) becomes widely ac-
cessible, and life expectancy improves [21]. However,
in economically disadvantaged regions such as sub-
Saharan Africa where the HIV population is dispro-
portionately concentrated, only a small percentage of
those in need are expected to have access to renal
replacement therapy [21–23]. CAPD is a relatively
inexpensive, easily learned, and readily implemented
dialysis option that does not require complex equip-
ment [1–3, 18]. As such, it is particularly well suited
as a home dialysis modality in regions where dialysis
facilities are limited. However, peritonitis may com-
plicate the use of CAPD in patients with ESRD and
HIV. This study aimed to evaluate the effects of HIV
infection on CAPD-associated peritonitis rates and
outcomes, and to assess risk factors associated with
the development of peritonitis and technique failure
in HAART-treated HIV-positive CAPD populations.
Methods
The study protocol was approved by the University of
KwaZulu-Natal Biomedical Research Ethics Committee
(BE 187/11), and research was conducted in accordance
with the principles of the Declaration of Helsinki. All
participants provided written informed consent prior to
study enrollment.
Sites
We recruited patients for a prospective cohort study
from two hospitals in Durban, South Africa between
September 2012 and February 2015. King Edward VIII
Hospital (KEH) is a 799-bed regional referral center with
limited specialist services. Inkosi Albert Luthuli Central
Hospital (IALCH) is an 846-bed specialist referral hos-
pital for KwaZulu-Natal province and covers a catch-
ment area of approximately 10 million people. The renal
unit based in IALCH offers CAPD (total patient popula-
tion of 220), hemodialysis (150 patients), and transplant-
ation services.
Study population
We enrolled 70 HIV-negative and 70 HIV-positive pa-
tients with end-stage renal failure who underwent dialy-
sis with a newly inserted double-cuffed coiled Tenckhoff
catheter at the two hospitals. Patients with incident
CAPD aged 18–60 years were consecutively recruited
soon after Tenckhoff insertion until each cohort reached
the 70-patient target. Peritonitis rate differentials re-
ported by previous similar studies were used to calculate
the sample size required to achieve a power of 80% and
an α error probability of 0.05 [8]. The HIV infection sta-
tus was determined by two 4th generation HIV enzyme-
linked immunosorbent assays (ELISA) performed by the
South African National Health Laboratory Service
(NHLS) before enrollment, screening for HIV performed
using a HIV Ag/Ab Combo (CHIV) assay (ADVIA Cen-
taur® XP, Siemens Healthcare Diagnostics, Tarrytown,
NY, USA) and confirmation using HIV Combi and HIV
Combi PT assays (Cobas e601, Roche Diagnostics,
Mannheim, Germany). HAART management was left to
the discretion of the local clinic. Tenckhoff catheter
insertion was performed by experienced surgeons by
laparoscopy (66 HIV-negative and 35 HIV-positive pa-
tients) at IALCH, and by trained nephrologists percu-
taneously at KEH (4 HIV-negative and 20 HIV-positive
patients) and IALCH (15 HIV-positive patients). All
CAPD patients utilized Y-sets, twin-bag systems, and
conventional peritoneal dialysis (PD) solutions (Dianeal
1.5, 2.5, or 4.25% dextrose, icodextrin, or amino acid-
based solutions; Baxter Healthcare, Deerfield, IL, US).
They were trained predominantly as outpatients by the
same nursing team, and generally performed four
exchanges per day.
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Enrollment and follow-up
On enrollment, demographic, clinical, and biochemical
data were recorded. All patients were followed-up at a
central renal clinic at IALCH monthly for 18 months or
until the endpoints of catheter removal or death. At each
follow-up, vital signs, clinical assessment, anthropomet-
ric measurements, and phlebotomy for biochemical tests
were done by the research team, and details of periton-
itis events and hospital admissions in the intervening
period were recorded on predefined questionnaires. La-
boratory tests for full blood count, C-reactive protein
(CRP), and serum urea, creatinine, electrolytes, albumin,
and ferritin were performed by the NHLS, and results
were periodically retrieved from the IALCH electronic
results database.
Peritonitis episodes
A peritonitis episode was defined as a clinical presenta-
tion with a cloudy effluent or abdominal pain associated
with an effluent white blood cell count (WCC) of more
than 100 cells/μL or a positive PD effluent culture. The
diagnosis of peritonitis was made by the CAPD nurse
and the attending physician. The attending physician de-
cided whether to manage the case on an inpatient or
outpatient basis depending on the severity of the clinical
presentation. All patients initially received intraperito-
neal vancomycin and amikacin empirically, and further
therapy was modified according to culture results. Treat-
ment duration was typically two weeks unless extended
to three weeks by the attending physician due to the cul-
tured organism or response to treatment. Episodes of
peritonitis were recorded on predefined questionnaires
during monthly clinic visits along with the date of pres-
entation, whether treated as inpatient or outpatient, pre-
senting PD WCC, and the culture result retrieved from
the hospital electronic record. PD effluent WCCs were
manually assessed using a 40X microscope, and PD ef-
fluent culturing was performed by the NHLS microbiol-
ogy department using standard culturing techniques.
Peritonitis-associated hospital admission was defined
as an admission for which peritonitis was cited as one
of the indications or where peritonitis was diagnosed
during the admission. The hospitalization episodes
were recorded on the predefined questionnaire with the
date of admission and discharge, indications for, and
outcome of the admission. Catheter removal occurring
during a peritonitis-associated admission episode was
recorded as being related to peritonitis.
Multiple peritonitis episodes were classified as relapsing
if occurring within 4 weeks of completion of treatment for
a prior episode with the same organism or one sterile epi-
sode, recurrent if occurring within 4 weeks of completion
of treatment for a prior episode with a different organism,
or repeat if occurring more than 4 weeks after completion
of treatment for the prior episode [24].
Endpoints
All Tenckhoff catheters were removed at IALCH. The
indications for removal and the corresponding date were
recorded as study endpoints. Technique failure was de-
fined as catheter removal due to catheter malfunction or
infection. The in-hospital mortality dates at IALCH and
certified causes of death were recorded. Deaths occur-
ring outside IALCH were recorded as home deaths, and
the corresponding details were obtained via telephone
interviews with the participants’ relatives.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation or medians (interquartile range [IQR]) and
were compared using the Student’s t-test or Wilcoxon-
Mann-Whitney test as appropriate. Proportions and
categorical variables were compared using Pearson’s
chi-square test or Fisher’s exact test as appropriate.
Survival estimates were computed using the Kaplan–
Meier method, and the log-rank test was used to com-
pare survival curves. Univariate Cox regression survival
analysis was used to estimate the association between
HIV, associated subgroups, and various risk factors for
outcome variables. Multivariable Cox regression analysis
was used to identify independent predictors of survival.
All analyses were performed using Stata Statistical Soft-
ware, Release 13 (StataCorp, College Station, Texas, US).
The level of significance was set at P < 0.05.
Results
Patient characteristics
The mean patient age was 39.1 ± 11.7 (HIV-negative)
and 37.0 ± 9.4 (HIV-positive) years with women account-
ing for 42.9 and 52.9% of the two cohorts, respectively.
All patients (100%) in the HIV-positive cohort were of
African ethnicity compared to 84.3% in the HIV-
negative cohort (P = 0.003). Fifty-one percent of HIV-
positive patients were either newly diagnosed with HIV
or had recently started HAART (less than six months
before insertion of the Tenckhoff catheter). However,
57.1% of HIV-positive patients had a suppressed viral
load (<150 copies/mL, hospital laboratory assay limit) at
the time of enrollment. While the median baseline viral
load was 4230 copies/mL (IQR, 903–91,143) for patients
with detectable viral loads, the median dropped below
the detectable limit (IQR <150–2990) when including
patients with undetectable viral loads. Twenty-one per-
cent of HIV-positive patients had CD4 counts >500
cells/μL, 20.0% had <200 cells/μL, and the remainder
(58.6%) had 200–500 cells/μL. Other details of the study
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population are outlined in Table 1 and were previously
described in our report on 1-year outcomes [25].
Study end points
After 18 months, 54.3% (38/70) of the HIV-negative co-
hort and 28.6% (20/70) of the HIV-positive cohort were
alive with a patent catheter (P = 0.002). Technique failure
occurred in 24.3% (17/70) of the HIV-negative cohort and
27.1% (19/70) of the HIV-positive cohort (P = 0.699),
whereas 18.8% (13/70) and 40.0% (28/70), respectively,
died (P = 0.005). One HIV-negative cohort participant and
two HIV-positive participants had their Tenckhoff cathe-
ters removed due to improved renal function. One HIV-
negative participant underwent kidney transplantation
from a live related donor, and one HIV-positive partici-
pant left the study to undergo private hemodialysis and
was lost to follow-up.
Peritonitis episodes
There were 54 peritonitis episodes observed in 44.3%
(31/70) of the HIV-negative cohort and 94 episodes in
65.7% (46/70) of the HIV-positive cohort during the
follow-up period (P = 0.011). Fifty-one percent (36/70) of






Age (mean ± SD) 39.1 ± 11.7 37.0 ± 9.4 0.247a
Weight, kg (mean ± SD) 68.9 ± 12.6 66.1 ± 13.7 0.213a
Body mass index (mean ± SD) 25.1 ± 4.7 24.5 ± 5.4 0.436a
Waist circumference, cm
(mean ± SD)
90.5 ± 10.9 90.0 ± 11.5 0.822a
Sex
Female, n (%) 30 (42.9) 37 (52.9) 0.236b
Ethnicity
African, n (%) 59 (84.3) 70 (100.0) 0.001c
Indian, n (%) 9 (12.9) 0 (0.0)
Mixed ethnicity, n (%) 2 (2.9) 0 (0.0)
Hypertension, n (%) 63 (90.0) 52 (74.3) 0.015b
Diabetes, n (%) 4 (5.7) 7 (10.0) 0.532c
SLE, n (%) 4 (5.7) 1 (1.4) 0.366 c
Hepatitis B, n (%) 7 (10.0) 8 (12.1) 0.737b
Primary residence
City, n (%) 14 (20.0) 6 (8.6) 0.113b
Townshipe, n (%) 30 (42.8) 39 (55.7)
Rural, n (%) 23 (32.9) 24 (34.3)
Education level
Primary school, n (%) 15 (21.4) 13 (18.6) 0.710b
High school, n (%) 32 (45.7) 31 (44.3)
Post-grade 12, n (%) 20 (28.6) 25 (35.7)
Employment history
Unemployed, n (%) 50 (71.4) 53 (75.7) 0.766b
Employed, n (%) 17 (24.3) 16 (22.9)
Smoking (currently) 4 (5.71) 7 (10.0) 0.532c
Tenckhoff catheter insertion method
Laparoscopic, n (%) 66 (94.3) 35 (50.0) <0.001c
Percutaneous, n (%) 4 (5.71) 35 (50.0)
Hemoglobin, g/dL (mean ± SD) 9.60 ± 2.01 8.96 ± 1.61 0.041a
Albumin, g/L (mean ± SD) 35.3 ± 6.7 31.0 ± 6.6 <0.001a
eGFR, ml/min/1.73 m2
(mean ± SD)






CRP (mg/L), median (IQR) 19 (6–35) 56.5 (21–108) <0.001d
ESR (mm/hr), median (IQR) 49 (29–66) 88 (50–129) <0.001d




mean (cells/μL ± SD) 380.7 ± 235.4
CD4 < 200 cells/μL, n (%) 14.0 (20.0)
CD4 200–350 cells/μL, n (%) 20.0 (28.6)
Table 1 Baseline characteristics (Continued)
CD4 350–500 cells/μL, n (%) 21.0 (30.0)
CD4≥ 500 cells/μL, n (%) 15.0 (21.4)
Viral load
Median, copies/mL (IQR) 4230
(903–91143)
< 150 copies/mL, n (%) 40 (57.1)
150–1000 copies/mL, n (%) 8 (11.4)
> 1000 copies/mL, n (%) 22 (31.4)
HAART history at enrollment
< 6 months, n (%) 36 (51.4)
6–12 months, n (%) 9 (12.9)
> 1 year, n (%) 25 (35.7)
HAART drug regimens
3TC/EFV/ABC, n (%) 59 (84.3)
3TC/EFV/AZT, n (%) 2 (2.9)
3TC/EFV/D4T, n (%) 3 (4.3)
3TC/NVP/ABC, n (%) 3 (4.3)
3TC/Alluvia/ABC, n (%) 1 (1.43)
3TC/Aluvia/AZT, n (%) 1 (1.43)
SLE systemic lupus erythematosus, eGFR estimated glomerular filtration rate
(MDRD equation), HAART highly active anti-retroviral therapy, ESR erythrocyte
sedimentation rate, CD cluster of differentiation, 3TC Lamivudine, EFV Efavirenz,
ABC Abacavir, AZT Zidovudine, D4T Stavudine, NVP Nevirapine, CRP C-reactive
protein, HIV human immunodeficiency virus
aStudent’s t-test, bPearson’s χ2 test, cFisher’s exact test,
dWilcoxon-Mann-Whitney test
eSouth African Township refers to underdeveloped urban areas created under
apartheid for non-white residents
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the HIV-positive cohort participants had one or more
peritonitis episodes in the first 180 days following
Tenckhoff catheter insertion compared to 24.3% (17/
70) in the HIV-negative cohort (P = 0.002). Nine per-
cent (5/54) of peritonitis episodes in the HIV-negative
cohort and 13.8% (13/94) in the HIV-positive cohort
were relapse episodes (P = 0.602). Eleven percent (6/54)
of peritonitis episodes in the HIV-negative cohort and
7.4% (7/94) in the HIV-positive cohort were repeat epi-
sodes with the same organism (P = 0.448), while 18.5%
(10/54) in the HIV-negative cohort and 23.4% (22/94)
in the HIV-positive cohort were repeat episodes with a
different organism (P = 0.487) (Table 2).
The HIV-negative cohort had a higher proportion of
Gram-negative peritonitis episodes (44.4%, 24/54)
compared to the HIV-positive cohort (27.7%, 26/94)
(P = 0.038). Culture-negative results were seen in
18.5% (10/54) of HIV-negative and 28.7% (27/94) of
HIV-positive cohort episodes (P = 0.17) (Table 3). The
majority of the peritonitis episodes, 70.4% (38/54) in
the HIV-negative cohort and 78.7% (74/94) in the
HIV-positive cohort, were successfully treated without
discontinuation of CAPD. Peritonitis resulted in cath-
eter removal in 25.9% (14/54) of HIV-negative cases
and 17.0% (16/94) of HIV-positive cases accounting
for 82.4% (14/17) and 84.2% (16/19) of all technique
failures in each cohort, respectively. A small propor-
tion of peritonitis episodes (3.7% (2/54) in the HIV-
negative group and 4.3% (4/94) in the HIV-positive
group) ended in mortality during observed admissions,
accounting for 15.4% (2/13) and 14.3% (4/28) of all
deaths in each cohort respectively (Table 2).
Peritonitis rates and proportional hazard analysis
Overall peritonitis rates, excluding relapse episodes,
were 0.765 (HIV-negative cohort) and 1.855 (HIV-posi-
tive cohort) episodes/person-years (1/15.7 months and
1/6.5 months, respectively), with a Cox univariate pro-
portional hazard ratio of 2.41 (95% confidence interval
(CI), 1.69–3.45, P < 0.001) associated with HIV infection.
Kaplan-Meier peritonitis-free survival rates were 6.0%
(HIV-positive cohort) and 32.3% (HIV-negative cohort)
at 18 months (P < 0.001) (Fig. 1). When the baseline
CD4 count was below 200 cells/μL, the peritonitis rate
Table 2 Peritonitis outcomes at 18 months
HIV-Negative HIV-Positive P value
Peritonitis episodes, n (n excluding relapse)a 54 (49) 94 (81) 0.001b
Participants with a peritonitis episode at 180 dayse 24.3% (17/70) 51.4% (36/70) 0.001
Participants with a peritonitis episode at 1 yeare 38.6% (27/70) 60.0% (42/70) 0.011
Participants with a peritonitis episode at 18 monthse 44.3% (31/70) 65.7% (46/70) 0.011
Multiple peritonitis episodes
Time between peritonitis episodes (days), median (IQR) 75 (39–107) 55.5 (34.5–115.5) 0.503d
Relapse 9.2% (5/54) 13.8% (13/94) 0.602c
Recurrent 3.7% (2/54) 6.4% (6/94) 0.711c
Repeat (Same organism) 11.1% (6/54) 7.4% (7/94) 0.448b
Repeat (Different organism) 18.5% (10/54) 23.4% (22/94) 0.487b
Time - Tenckhoff catheter insertion to peritonitis episode
Median, days (IQR) 184.5 (98–370) 144.5 (63–296) 0.124d
Within 180 days 50.0% (27/54) 56.4% (53/94) 0.453b
Between 180 – 365 days 24.1% (13/54) 27.7% (26/94) 0.634b
Between 365 – 550 days 25.9% (14/54) 16.0% (15/94) 0.141b
PD WCC (cells/μl), median (IQR) 1073 (360–2690) 979 (360–2370) 0.927d
Outpatient treatment 33.3% (18/54) 40.4% (38/94) 0.392b
Inpatient treatment 66.7% (36/54) 59.6% (56/94) 0.392b
Inpatient stay (days), median (IQR) 9 (7–12) 8 (7–14.5) 0.574d
Peritonitis episode outcomes
CAPD continuation 70.4% (38/54) 78.7% (74/94) 0.254b
Catheter removal 25.9% (14/54) 17.0% (16/94) 0.195b
Mortality 3.7% (2/54) 4.3% (4/94) 1.000c
IQR interquartile range, PD peritoneal dialysis, WCC white blood cell count, CAPD continuous ambulatory peritoneal dialysis, HIV human immunodeficiency virus
aPeritonitis episode count excluding peritonitis relapse, bPearson’s χ2 test, cFisher’s exact test
dWilcoxon rank-sum (Mann-Whitney) test, ePeritonitis experience – documented 1 or more of peritonitis episodes
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rose to 3.690 episodes/person-years (HR 4.54, 95% CI
2.35–8.76, P < 0.001), while a baseline CD4 count
above 350 cells/μL was associated with a peritonitis
rate of 1.599 episodes/person-years (HR 2.10, CI 1.39–
3.15, P = 0.001). The peritonitis relapse rate was 0.078
(HIV-negative cohort) and 0.298 (HIV-positive cohort)
episodes/person-years (HR 3.88, CI 1.37–10.94, P =
0.01) (Table 4).
On multivariable analysis, HIV (HR 1.84, 95% CI
1.07–3.16, P = 0.03), diabetes, and a baseline CD4 count
less than 200 cells/μL were found to be independent
predictors of peritonitis (Table 5).
Table 3 Peritonitis episode culture results
HIV-Negative HIV-Positive P value
All peritonitis episodes
Gram-positive 33.3% (18/54) 36.2% (34/94) 0.728a
Staphylococcus aureus 16.7% (9/54) 7.4% (7/94) 0.082a
Coagulase-negative staphylococcus 16.7% (9/54) 23.4% (22/94) 0.332a
Other gram-positive bacteria 0.0% (0/54) 5.3% (5/94) 0.159b
Gram-negative 44.4% (24/54) 27.7% (26/94) 0.038a
Pseudomonas species 13.0% (7/54) 6.4% (6/94) 0.173a
Klebsiella pneumoniae 5.6% (3/54) 4.3% (4/94) 0.706b
Acinetobacter species 3.7% (2/54) 10.6% (10/94) 0.212b
Other gram-negative bacteria 22.2% (12/54) 6.4% (6/94) 0.005a
Mixed organisms 0.0% (0/54) 1.1% (1/94) 1.000b
Fungal peritonitis 3.7% (2/54) 5.3% (5/94) 1.000b
Mycobacterium tuberculosis 0.0% (0/54) 1.1% (1/94) 1.000b
Culture-negative 18.5% (10/54) 28.7% (27/94) 0.168a
Peritonitis relapse episodes
Coagulase-negative staphylococcus 1.8% (1/54) 3.2% (3/94) 1.000b
Other gram-positive bacteria 0.0% (0/54) 1.1% (1/94) 1.000b
Pseudomonas species 1.8% (1/54) 3.2% (3/94) 1.000b
Other gram-negative bacteria 1.8% (1/54) 1.1% (1/94) 1.000b
Culture-negative 3.7% (2/54)c 4.3% (4/94)d 1.000b
Mycobacterium tuberculosis 0.0% (0/54) 1.1% (1/94) 1.000b
Peritonitis-associated catheter removal
Staphylococcus aureus 1.8% (1/54) 0 0.365b
Pseudomonas species 9.3% (5/54) 1.1% (1/94) 0.025b
Acinetobacter species 1.8% (1/54) 6.4% (6/94) 0.423b
Other gram-negative bacteria 5.6% (3/54) 1.1% (1/94) 0.138b
Culture-negative 3.7% (2/54) 3.2% (3/94) 1.000b
Candida species 3.7% (2/54) 4.2% (4/94) 1.000b
Mycobacterium tuberculosis 0 1.1% (1/94)e 1.000b
Peritonitis-associated mortality
Coagulase-negative staphylococcus 1.8% (1/54) 1.1% (1/94) 1.000b
Escherichia coli 1.8% (1/54) 1.1% (1/94) 1.000b
Fungal Peritonitis 0 1.1% (1/94) 1.000b
Culture-negative 0 1.1% (1/94) 1.000b
HIV human immunodeficiency virus
aPearson’s χ2 test, bFisher’s exact test
cOne relapse episode first presented as Staphylococcus aureus peritonitis then relapsed as culture-negative peritonitis
dTwo relapse episodes first presented as Pseudomonas aeruginosa peritonitis then relapsed as culture-negative peritonitis
eFirst presented as culture-negative peritonitis then relapsed as Mycobacterium tuberculosis
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Technique failure
All-cause technique failure rates were 0.237 (HIV-nega-
tive cohort) and 0.338 (HIV-positive cohort) episodes/
person-years (HR 1.42, 95% CI 0.73–2.73, P = 0.299).
Kaplan-Meier technique survival rates at 18 months
censored for death, catheter removal not related to
technique failure, and loss to follow-up were 71.4%
(HIV-negative cohort) and 58.2% (HIV-positive cohort),
respectively (P = 0.295) (Fig. 2). Fifty-three percent (9/
17) of technique failures in the HIV-negative cohort
and 42.1% (8/19) in the HIV-positive cohort were due to
gram-negative peritonitis episodes (P = 0.516). Fungal
peritonitis was responsible for 11.8% (2/17) (HIV-negative
cohort) and 21.0% (4/19) (HIV-positive cohort) of the
technique failures (P = 0.662). Multivariable proportional
hazard analysis identified peritonitis (HR 14.47, CI 2.79–
75.00, P = 0.001), average hemoglobin concentration and
average serum CRP level as independent predictors of
technique failure (Table 5). Participants with one or
more episodes of peritonitis during follow-up had an
18-month survival rate (Kaplan-Meier technique) of
47.5% compared to 93.9% for those who did not experi-
ence peritonitis (P < 0.0001) (Fig. 3).
Discussion
This prospective cohort study evaluated the effect of
HIV infection on CAPD-associated peritonitis outcomes
in patients with ESRD requiring dialysis. At 18 months,
HIV was associated with an increased risk (HR 2.41) of
developing peritonitis with rates of 1.86 episodes/
person-years compared to 0.76 episodes/person-years for
HIV-negative CAPD patients. Our HIV-negative periton-
itis rate was higher than the target rate of 0.67/year-at-
risk advocated by the 2010 International Society for
Peritoneal Dialysis (ISPD) guidelines, probably reflecting
a higher intrinsic risk in our patient population which is
predominantly impoverished with few available choices
for alternative hemodialysis [24].
The few retrospective studies that have examined the
outcomes of CAPD in HIV-infected patients have dem-
onstrated improvements in survival and reductions in
peritonitis rates associated with the use of HAART and
advances in CAPD [8, 17, 26]. However, to our know-
ledge, our study is the first to prospectively evaluate the
effects of HIV infection and duration of HAART on
peritonitis outcomes among ESRD patients on CAPD.
Our HIV-positive CAPD-associated peritonitis rate was
much lower than the 3.9 episodes/patient-year reported
over 20 years ago by Tebben et al. [17], reflecting a de-
creased risk associated with the greater availability of
HAART over the years. Further, the authors reported a
decreased peritonitis rate of 2.6 episodes/patient-year for
HIV-positive patients using the Y-disconnect system,
highlighting improved outcomes associated with tech-
nique enhancements. Khanna et al. [8] reported a lower
peritonitis rate of 1.4 episodes/patient-year at the be-
ginning of the HAART era; however, little information
was provided on the characteristics of their HIV-
positive CAPD population. Our state-sponsored renal
replacement program practices a “PD first” policy
directing that all dialysis-requiring ESRD patients be
routinely started on CAPD. Limited hemodialysis slots
are thereby reserved for those who fail CAPD or have
medical contraindications to CAPD. This unselective
policy determining our CAPD patient population along
with the low educational levels and socioeconomic sta-
tus of our patients (a majority being unemployed, living
in impoverished areas, and not having completed grade
12) may have contributed to an increased intrinsic peri-
tonitis risk [14, 27, 28].
Although HIV and diabetes were identified as inde-
pendent predictors of poor peritonitis outcome, the
immunologic state also modified the HIV-associated
risk. A baseline CD4 count <200 cells/μL increased
the hazards for peritonitis more than 4-fold compared
to HIV-negative CAPD patients (3.69 episodes/per-
son-years, HR 4.54, P < 0.001). This probably reflects
compromised host defense mechanisms against infec-
tious organisms at lower CD4 counts. A baseline CD4
count above 350 cells/μL was associated with a 2-fold
increased hazard for peritonitis (1.60 episodes/person-
years, HR 2.10, P = 0.001), further highlighting the
inherent risk associated with HIV infection even with
higher CD4 counts. The peritonitis risk was demon-
strated to manifest early, as within 180 days following
Tenckhoff catheter insertion half of the HIV-positive
cohort had at least one documented episode of peri-
tonitis. This risk was shown to persist, as demon-
strated by the peritonitis-free survival rate of only
6.0% at 18 months.
Fig. 1 Kaplan-Meier survival estimates for peritonitis episodes
excluding relapses censored for mortality, catheter loss, and loss to
follow-up HIV = human immunodeficiency virus
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The HIV-positive cohort showed an increased gram-
positive peritonitis rate compared to the HIV-negative
cohort (0.68 vs. 0.26 episodes/person-years, HR 2.59,
P = 0.001), possibly reflecting a greater susceptibility to
touch contamination-related infection due to compro-
mised local defense mechanisms contributing to the
HIV-associated peritonitis risk. This finding suggests a
role for a prophylactic antibiotic strategy, particularly
in the first six months following catheter insertion
when the peritonitis risk is highest and more so among
patients with low CD4 counts. The HIV-positive co-
hort also had a significantly increased culture-negative
peritonitis rate compared to the HIV-negative cohort
(0.56 vs. 0.15 episodes/person-years, HR 3.64, P =
0.001). Culture negative cases accounted for 28.7% of
the HIV-positive cohort’s total peritonitis episodes;
this percentage is above the 20% recommended by the
2010 ISPD guidelines. This finding could indicate a
higher prevalence of fastidious organisms and myco-
bacteria in this group [29, 30].
Peritonitis was shown to be the predominant cause of
technique failure in both cohorts and was further
identified as an independent predictor of this outcome.
Although HIV was associated with an increased risk of
peritonitis as well as an increased risk for subsequent
episodes, it was not shown to significantly influence all-
cause technique failure rates (HR 1.42, P = 0.299) or
peritonitis-associated technique failure rates (HR 1.43,
P = 0.335). This inconsistency may be partially explained
by the significantly higher proportion of gram-negative
peritonitis episodes documented in the HIV-negative co-
hort (44.4 vs. 27.7%, P = 0.038); gram-negative organisms
Table 4 Incidence rates and Cox proportional hazard univariate analysis
Incidence rates per person-year HIV-Negative HIV-Positive Hazard ratio
(95% Conf. Interval)
P value
All-cause peritonitisa 0.765 1.855 HR 2.41 (1.69–3.45) <0.001
Baseline CD4 count
< 200 cells/μL 3.690 HR 4.54 (2.35–8.76) <0.001
200–350 cells/μL 1.940 HR 2.61 (1.60–4.24) <0.001
> 350 cells/μL 1.599 HR 2.10 (1.39–3.15) 0.001
Gram-positive peritonitis 0.262 0.675 HR 2.59 (1.46–4.60) 0.001
Gram-negative peritonitis 0.353 0.512 HR 1.40 (0.80–2.44) 0.236
Culture-negative peritonitis 0.150 0.560 HR 3.64 (1.75–7.54) 0.001
Fungal peritonitis 0.028 0.089 HR 3.25 (0.63–16.79) 0.159
Peritonitis relapse 0.078 0.298 HR 3.88 (1.37–10.94) 0.010
Baseline CD4 count
< 200 cells/μL 0.615 HR 10.60 (1.95–57.56) 0.006b
200–350 cells/μL 0.698 HR 8.82 (2.90–26.90) <0.001b
≥ 350 cells/μL 0.073 HR 0.97 (0.19–5.00) 0.969b
Peritonitis recurrence 0.031 0.137 HR 4.62 (0.92–23.21) 0.063
Peritonitis repeat (same organism) 0.094 0.160 HR 1.81 (0.60–5.42) 0.289
Peritonitis repeat (different organism) 0.156 0.504 HR 3.81 (1.80–8.09) <0.001
Multiple peritonitisa 0.281 0.802 HR 3.22 (1.82–5.71) <0.001
Baseline CD4 count
< 200 cells/μL 1.230 HR 8.41 (2.71–26.08) <0.001b
200–350 cells/μL 0.931 HR 3.90 (1.86–8.18) <0.001b
> 350 cells/μL 0.690 HR 2.64 (1.38–5.04) 0.003b
Peritonitis hospital admissions 0.815 1.814 HR 2.19 (1.44–3.35) <0.001
Peritonitis technique failurec 0.195 0.285 HR 1.43 (0.69–2.93) 0.335
All-cause technique failured 0.237 0.338 HR 1.42 (0.73–2.73) 0.299
Peritonitis mortality 0.028 0.071 HR 2.67 (0.49–14.60) 0.258
All-cause mortality 0.181 0.498 HR 2.53 (1.31–4.90) 0.006
HR hazard ratio, CD cluster of differentiation, HIV human immunodeficiency virus
a Excluding peritonitis relapse episodes; b HIV-positive sub-groups compared to the HIV-negative cohort; c Peritonitis technique failure - catheter removal due to
peritonitis; d Technique failure - catheter removal due to catheter malfunction or infection
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were also the major causative organism group for
technique failures in both cohorts (52.9% and 42.1%,
respectively). It may be that HIV infection does not
increase the risk of catheter-threatening peritonitis in
the first 18 months following insertion but instead
increases the risk for treatable peritonitis episodes.
However, increased relapses and multiple episodes
raise concern about the long-term risk of technique
failure. Further, the disproportionately higher mortal-
ity rate in the HIV-positive cohort contributed to a
dropout rate of 44.3% compared to 21.4% in the HIV-
negative cohort; this may have introduced bias, result-
ing in a lower apparent rate of technique failure in the
HIV-positive cohort.
The major limitation of our study is that it is a
single-center observational study, which inherently
limits causation inferences that can be drawn from
observed associations. Statistical power, particularly
relating to technique failure outcomes, was limited by
the relatively small sample size and short follow-up
period. The matching strategy of restricting the inclu-
sion age to 18–60 years may limit the generalizability of
Table 5 Cox proportional hazard univariate and multivariate analyses: risk factors vs. peritonitis and technique failure
Univariate Cox proportional hazards Multivariable Cox proportional hazards
Variable Hazard ratio
(95% Conf. Interval)




HIV 2.41 (1.69–3.45) <0.001 1.84 (1.07–3.16) 0.027
Race 0.19 (0.06–0.57 0.003 0.54 (0.05–5.66) 0.607
Catheter insertion methoda 1.86 (1.28–2.71) 0.001 0.63 (0.28–1.42) 0.269
Catheter insertion siteb 2.20 (1.45–3.33 <0.001 2.17 (0.84–5.58) 0.108
Diabetes 2.22 (1.35–3.66) 0.002 2.09 (1.09–4.03) 0.027
BMI 1.04 (1.00–1.08 0.033 1.01 (0.95–1.09) 0.720
Waist circumference 1.02 (1.00–1.04) 0.017 1.03 (0.99–1.06) 0.151
Baseline hemoglobin 0.85 (0.77–0.94) 0.002 1.02 (0.88–1.19) 0.786
Baseline albumin 0.95 (0.93–0.98) 0.001 0.98 (0.94–1.02) 0.298
Baseline CRP 1.00 (1.00–1.01) 0.004 1.00 (1.00–1.00) 0.652
Baseline CD4 count (cells/µL)
HIV-negative Reference
CD4 < 200 4.54 (2.35–8.76) <0.001 3.28 (1.42–7.61) 0.006
CD4 200–350 2.61 (1.6–4.24) <0.001 1.18 (0.66–2.12) 0.577
CD4 ≥ 350 2.10 (1.39–3.15) <0.001 1.00
Residence
City Reference
Townshipc 5.94 (2.17–16.25) 0.001 5.56 (0.82–37.50) 0.078
Rural area 6.07 (2.19–16.8) 0.001 4.68 (0.70–31.07) 0.110
Technique failuree
HIV 1.42 (0.73–2.73) 0.299 0.39 (0.14–1.11) 0.077
Peritonitis 9.29 (2.84–30.36) <0.001 14.47 (2.79–75.00) 0.001
Catheter insertion site 2.33 (1.09–4.97) 0.029 2.73 (0.49–15.21) 0.252
Catheter insertion method 1.62 (0.79–3.30) 0.185 0.69 (0.13–3.71) 0.663
Average hemoglobin 0.72 (0.59–0.88) 0.001 0.75 (0.59–0.95) 0.016
Average CRP 1.02 (1.01–1.02) <0.001 1.02 (1.01–1.03) <0.001
BMI Body mass index, CD cluster of differentiation, CRP C-reactive protein, HIV human immunodeficiency virus
aCatheter insertion method- laparoscopic vs. percutaneous, bCatheter insertion site - Inkosi Albert Luthuli Central Hospital vs King Edward VIII Hospital,
cSouth African Township refers to underdeveloped urban areas created under apartheid for non-white residents
dAdjusted for age, race, gender, smoking, diabetes, body mass index, waist circumference, baseline hemoglobin, baseline serum albumin, baseline C-reactive protein,
primary residence, highest education level, employment, baseline CD4 count, Tenckhoff catheter insertion site, and Tenckhoff catheter insertion method (laparoscopic
vs. percutaneous)
eAdjusted for HIV, peritonitis, age, gender, smoking, diabetes, body mass index, waist circumference, average hemoglobin, average C-reactive protein, average
serum ferritin, primary residence, highest education level, employment, Tenckhoff catheter insertion site, and Tenckhoff catheter insertion method (laparoscopic
vs. percutaneous)
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our results to only this age group. This matching strat-
egy was employed to minimize age as a confounding
factor, as HIV-positive CAPD populations are typically
younger than their HIV-negative counterparts [8, 17].
More studies are needed to assess outcomes of renal
replacement modalities in various HIV-positive ESRD
populations.
Conclusions
Our study indicates that HIV infection can adversely
influence CAPD-associated peritonitis rates, and this
association is further modified by the immunological
state of the infected patient. The peritonitis risk attrib-
utable to HIV infection manifests early in the course of
CAPD treatment and increases the risk for subsequent
episodes, but it was not shown to result in increased
technique failure rates at 18 months. Early detection of
CKD and HIV with the initiation of HAART before sig-
nificant immunological compromise and careful man-
agement of comorbid conditions can help minimize the
risk. Prophylactic antibiotics should be considered and
investigated as possible strategies to help improve peri-
tonitis outcomes.
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Fig. 2 Kaplan-Meier estimates for catheter patency according to HIV
status censored for mortality, loss to follow-up, and catheter removal
unrelated to technique failure HIV = human immunodeficiency virus
Fig. 3 Kaplan-Meier estimates for catheter patency according to
peritonitis experience (1 or more peritonitis episodes during follow-up)
censored for mortality, loss to follow-up, and catheter removal
unrelated to catheter failure
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